Joseph G. Pressey · Herpes simplex virus oncolytic therapy for pediatric malignancies
Follow
Article1 min read·Published Apr 2009Older

Herpes simplex virus oncolytic therapy for pediatric malignancies

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Apr 2009 · 1 min read

In brief

In brief

This review examines oncolytic herpes simplex virus therapy as an emerging treatment for chemotherapy-resistant pediatric cancers including brain tumors, neuroblastomas, and sarcomas. The article discusses therapeutic potential and translational challenges that must be overcome before clinical implementation in children.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Despite improving survival rates for children with cancer, a subset of patients exist with disease resistant to traditional therapies such as surgery, chemotherapy, and radiation. These patients require newer, targeted treatments used alone or in combination with more traditional approaches. Oncolytic herpes simplex virus (HSV) is one of these newer therapies that offer promise for several difficult to treat pediatric malignancies. The potential benefit of HSV therapy in pediatric solid tumors including brain tumors, neuroblastomas, and sarcomas is reviewed along with the many challenges that need to be addressed prior to moving oncolytic HSV therapy from the laboratory to the beside in the pediatric population.

Statements in this article

  1. A subset of pediatric cancer patients have disease resistant to traditional therapies such as surgery, chemotherapy, and radiation.

    Established
  2. Patients with treatment-resistant pediatric cancers require newer, targeted treatments used alone or in combination with more traditional approaches.

    Recommendation
  3. Oncolytic herpes simplex virus (HSV) offers promise for several difficult to treat pediatric malignancies.

    Research
  4. Oncolytic HSV therapy has potential benefit in pediatric solid tumors including brain tumors, neuroblastomas, and sarcomas.

    Research
  5. Many challenges need to be addressed prior to moving oncolytic HSV therapy from the laboratory to the bedside in the pediatric population.

    Open

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.